Viva 5 Announces Probiotic Licensing Agreement for Innovative New Patented Synbiotic

Viva 5 will be launching with selected partners in 2018 – 2019 and expect this ‘true synbiotic’ to be a boost to the Probiotic Category

FOR IMMEDIATE RELEASE
March 2018
Contact: Stacey Gillespie
+1-954-331-8153

SUNRISE, FL (March 5, 2018) — Viva 5 Corporation, a US-based probiotic specialist, announces they have entered into a licensing agreement with NUtech Ventures, the technology commercialization affiliate for the University of Nebraska­–Lincoln, to be the exclusive worldwide distributor of an innovative new synbiotic, combining a proprietary human strain of Bifidobacterium adolescentis with a carefully selected galactooligosaccharide (GOS) prebiotic.

Prebiotics are nondigestible food ingredients that promote the growth of beneficial microorganisms (probiotics) in the intestines. A synbiotic is a probiotic-prebiotic combination that selectively supports growth of the probiotic in the host. Viva 5 Corporation’s newly licensed patent-pending synbiotic utilizes a human probiotic strain, Bifidobacterium adolescentis IVS-1, isolated via a novel prebiotic enrichment strategy, known as In Vivo Selection (IVS). The synbiotic, formulated by researchers at University of Nebraska­–Lincoln, enriches for B. adolescentis IVS-1 and is backed by both preclinical and clinical research.

“Most, if not all, of the synbiotics on the market have not been rationally formulated based on ecological criteria. They have been combined based on cost, marketing or limited (or no) scientific studies showing evidence for synergistic or additive effects,” says Albert Dahbour, Executive Vice President at Viva 5 Corporation.  “In a true synbiotic, the prebiotic should have high affinity for the probiotic, it should selectively support growth of the probiotic in the human intestinal tract and, ultimately, show a health benefit to the host.  Thus, Viva 5 now has in our opinion the first real synbiotic and we are looking to further invest in additional research. ”

“We’re excited to partner with Viva 5 for commercialization of the synbiotic product,” said Brad Roth, Executive Director of NUtech Ventures. “Their experience in product development and distribution provides an opportunity for broad applicability ofIVS-1.”

While probiotics are currently one of the most successful dietary supplement categories in North America, carefully formulated synbiotics backed by clinical research, such as IVS-1, represent a unique growth opportunity for the probiotic market. Viva 5 Corporation’s newly licensed synbiotic will be available in capsule, tablet, stick pack, and powder delivery forms and can be utilized as a stand-alone product or combined with other compatible ingredients.

Viva 5 will be launching this synbiotic with selected partners worldwide in 2018.

###

FOR FURTHER INFORMATION ABOUT THIS PRESS RELEASE OR ABOUT VIVA 5 CORPORATION, PLEASE CONTACT:

Stacey Gillespie
Viva 5 Corporation
Contact: Stacey Gillespie
+1-954-331-8153

ABOUT VIVA 5 CORPORATION

Viva 5 Corporation is a US and International leader in sourcing, product development, manufacturing, regulatory & marketing support for a variety of channels in the nutrition health & beauty, and pharmaceutical industries. Viva 5 specialties include the development of innovative, proprietary, and efficacious products that create incremental revenue opportunities for its distribution and retail partners worldwide. For more information, please visit www.viva5corp.com or call 1-954-331-8153.

ABOUT NUTECH VENTURES

NUtech Ventures is the technology commercialization affiliate for the University of Nebraska–Lincoln. For information and available technologies, visit nutechventures.org.